Lipocalin-2: a novel potential therapy for GVHD

Trends Immunol. 2024 Mar 27:S1471-4906(24)00049-8. doi: 10.1016/j.it.2024.03.004. Online ahead of print.ABSTRACTCzech et al. used mouse models of allogeneic hematopoietic stem cell transplantation (allo-HCT) to investigate the role of lipocalin-2 (LCN2) as a newfound regulator of intestinal graft-versus-host disease (GVHD). Administration of recombinant LCN2 protein after disease onset prevented GVHD progression, suggesting that it may play a role in reversing tissue damage that has already begun.PMID:38548552 | DOI:10.1016/j.it.2024.03.004

Source: Trends in Immunology - March 28, 2024 Category: Allergy & Immunology Authors: Kate A Markey Source Type: research